Cart
sales@molnova.com
IDH1-IN-1
CAS No. 1355326-21-4
IDH1-IN-1( Mutant IDH1-IN-1 )
Catalog No. M11452 CAS No. 1355326-21-4
Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 2MG | 37 | In Stock |
|
| 5MG | 62 | In Stock |
|
| 10MG | 95 | In Stock |
|
| 25MG | 183 | In Stock |
|
| 50MG | 257 | In Stock |
|
| 100MG | 375 | In Stock |
|
| 200MG | 507 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIDH1-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionMutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).
-
DescriptionMutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent); more bioactivity information in Patent WO2012009678A1(Example 135).
-
In Vitro——
-
In Vivo——
-
SynonymsMutant IDH1-IN-1
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
Recptormutant IDH1 R132H
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1355326-21-4
-
Formula Weight498.59
-
Molecular FormulaC30H31FN4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESO=C(NC1CCCCC1)C(N(C(CN2C3=CC=CC=C3N=C2)=O)C4=CC=CC(F)=C4)C5=CC=CC=C5C
-
Chemical Name2-(N-[2-(Benzimidazol-1-yl)acetyl]-3-fluoroanilino)-N-cyclohexyl-2-(2-methylphenyl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Janeta Popovici-Muller, et al. Patent WO2012009678 A
molnova catalog
related products
-
Daidzin
Daidzin is an isoflavone that has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.
-
11β-HSD1-IN-11
11β-HSd1-in-11 is a potent and competitive inhibitor of 11-β-hydroxysteroid dehydrogenase 1 (11β-HSD1) IN rats and humans with IC50 values of 0.34 μM and 0.13 μM, respectively.
-
IDH2R140Q-IN-2
IDH2R140Q-IN-2 is an orally active and potent IDH2R140Q inhibitor with an IC50 of 29 nM.IDH2R140Q-IN-2 possesses potential antitumour activity, reducing D2HG production in TF-1 cell lines carrying the IDH2R140Q mutation (IC50 of 10 nM) and inhibiting tumour tissue D2HG levels.
